Search

Your search keyword '"Griffin, Meagan"' showing total 11 results
Start Over Author "Griffin, Meagan"
11 results on '"Griffin, Meagan"'

2. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis

Author

Lin, Andrew, Flynn, Jessica, DeRespiris, Lauren, Figgins, Bradley, Griffin, Meagan, Lau, Carmen, Proli, Anthony, Devlin, Sean M., Cho, Christina, Tamari, Roni, Jakubowski, Ann A., Papadopoulos, Esperanza B., Giralt, Sergio A., Perales, Miguel-Angel, Seo, Susan K., and Shaffer, Brian

Published
2021
Full Text
View/download PDF

4. Effect of Melphalan Exposure in Patients with Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Author

Lin, Andrew, primary, Dahi, Parastoo B., additional, Flynn, Jessica, additional, Uruburo, Christian, additional, Mcgeary, Ian, additional, Schofield, Ryan, additional, Bhatt, Valkal, additional, DeRespiris, Lauren, additional, Figgins, Bradley, additional, Griffin, Meagan, additional, Lau, Carmen, additional, Proli, Anthony J., additional, Carlow, Dean, additional, Cho, Christina, additional, Lahoud, Oscar Boutros, additional, Perales, Miguel, additional, Sauter, Craig S., additional, Scordo, Michael, additional, and Shah, Gunjan L., additional

Published
2020
Full Text
View/download PDF

5. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience

Author

Lin, Andrew, primary, Maloy, Molly, additional, Su, Yiqi, additional, Bhatt, Valkal, additional, DeRespiris, Lauren, additional, Griffin, Meagan, additional, Lau, Carmen, additional, Proli, Anthony, additional, Barker, Juliet, additional, Shaffer, Brian, additional, Giralt, Sergio A., additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Papanicolaou, Genovefa A., additional, Seo, Susan K., additional, and Perales, Miguel‐Angel, additional

Published
2019
Full Text
View/download PDF

6. Lack of a Significant Pharmacokinetic Interaction between Letermovir and Calcineurin Inhibitors in Allogeneic HCT Recipients

Author

Maples, Kathryn T., primary, Maloy, Molly A., additional, Lin, Andrew, additional, DeRespiris, Lauren, additional, Griffin, Meagan, additional, Lau, Carmen, additional, Proli, Anthony J., additional, Papanicolaou, Genovefa A., additional, Seo, Susan K., additional, Barker, Juliet N., additional, Perales, Miguel-Angel, additional, Giralt, Sergio A., additional, and Bhatt, Valkal, additional

Published
2019
Full Text
View/download PDF

7. Letermovir in Allogeneic Hematopoietic Cell Transplantation: Beyond the Label

Author

Lin, Andrew, primary, Maloy, Molly A., additional, Bhatt, Valkal, additional, DeRespiris, Lauren, additional, Griffin, Meagan, additional, Lau, Carmen, additional, Proli, Anthony J., additional, Barker, Juliet N., additional, Shaffer, Brian C., additional, Giralt, Sergio A., additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Papanicolaou, Genovefa A., additional, Seo, Susan K., additional, and Perales, Miguel-Angel, additional

Published
2019
Full Text
View/download PDF

10. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis

Author

Lin, Andrew, Flynn, Jessica, DeRespiris, Lauren, Figgins, Bradley, Griffin, Meagan, Lau, Carmen, Proli, Anthony, Devlin, Sean M., Cho, Christina, Tamari, Roni, Jakubowski, Ann A., Papadopoulos, Esperanza B., Giralt, Sergio A., Perales, Miguel-Angel, Seo, Susan K., and Shaffer, Brian

Abstract

•Letermovir is effective in reducing clinically significant cytomegalovirus (CMV) infection in haploidentical or mismatched adult unrelated donor allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide-based graft-versus host-disease prophylaxis (letermovir, 21.9% versus no letermovir, 68.8%; P< .001).•Persistent CMV infection necessitating >28 days of therapy was more common in patients who did not receive letermovir (31.2% versus 6.2%; P = .02).•Late clinically significant CMV infection is rare if letermovir prophylaxis is continued beyond 14 weeks (1 of 24 patients; 4.2%).

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results